-
6. ANTINOCICEPTIVE ACTIVITY OF METHANOLIC EXTRACT OF ACMELLA ULIGINOSA (SW.) CASS
JOURNAL OF ETHNOPHARMACOLOGY
2011 ERA CO-AUTHOR -
7. ANTINOCICEPTIVE EFFECT OF THE ESSENTIAL OIL OF ZINGIBER ZERUMBET IN MICE: POSSIBLE MECHANISMS
JOURNAL OF ETHNOPHARMACOLOGY
2011 ERA MAIN AUTHOR -
8. ZERUMBONE?INDUCED ANTINOCICEPTION: INVOLVEMENT OF THE L?ARGININE?NITRIC OXIDE?CGMP?PKC?K+ATP CHANNEL PATHWAYS
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
2011 ISI CO-AUTHOR -
9. POSSIBLE PARTICIPATION OF NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE C/ATP?SENSITIVE K+ CHANNELS PATHWAY IN THE SYSTEMIC ANTINOCICEPTION OF FLAVOKAWIN B
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
2011 ISI CO-AUTHOR -
10. ANTI-INFLAMMATORY EFFECT OF ZERUMBONE ON ACUTE AND CHRONIC INFLAMMATION MODELS IN MICE
FITOTERAPIA
2010 ISI CO-AUTHOR
ACADEMIC QUALIFICATIONS
- Bachelor in Doktor Perubatan (2016)
- Master in Sains Perubatan (Anatomi) (2012)
EXPERTISE
- Gross Anatomy
- Embryology (Including Developmental Anatomy)
- Neuroanatomy
DR. MOHAMED HANIEF BIN KHALID
PENSYARAH PERUBATAN DU13
Faculty
Fakulti Perubatan Dan Sains Kesihatan
Biography
A lecturer from Fakulti Perubatan Dan Sains Kesihatan. Holds a Bachelor in Doktor Perubatan.
Usim Expert: https://expert.usim.edu.my/haniefkhalid
Phone: 03-42892000
E-mail: haniefkhalid@usim.edu.my
-
1. IN-SILICO EVALUATION OF ZERUMBONE IN PAIN RELATED RECEPTORS.
2024 GERAN PENYELIDIKAN USIM RACER ON GOING MAIN RESEARCHER -
2. PREVALENCE AND ASSOCIATION OF SOCIODEMOGRAPHIC FACTORS WITH KNOWLEDGE, ATTITUDE, AND PRACTICE OF VAPING/ E-CIGARETTE AMONG MEDICAL STUDENTS IN FIVE PUBLIC UNIVERSITIES IN MALAYSIA
2024 BIDUNI MIZANNIYAH ON GOING MAIN RESEARCHER -
3. COMPUTATIONAL BIOPHYSICS SIMULATIONS OF CARDAMOMIN BINDING TO CANNABINOID RECEPTORS TO UNRAVEL ITS MOLECULAR MECHANISMS
2023 GERAN PENYELIDIKAN USIM ON GOING CO-RESEARCHER -
4. FIRST AID TRAINING AND CERTIFICATION FOR CHILDCARE PROVIDER (FAT4CP)� AT CHILDCARE CENTER IN NEGERI SEMBILAN
2022 GERAN PENYELIDIKAN AGENSI KERAJAAN COMPLETED CO-RESEARCHER
Completed: 1 (25%)
Ongoing: 3 (75%)